Stevanato Group SPA STVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if STVN is a good fit for your portfolio.
News
-
Stevanato Group to Present at the Bank of America Securities Healthcare Conference
-
Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024
-
Stevanato Group appoints Ugo Gay as Chief Operations Officer
-
Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares
-
Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares
-
Stevanato Group Announces Public Offering of Ordinary Shares
-
Stevanato Group to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
-
Stevanato Group Delivers Double-Digit Revenue Growth in Fiscal Year 2023
Trading Information
- Previous Close Price
- $26.81
- Day Range
- $26.04–27.72
- 52-Week Range
- $23.00–36.30
- Bid/Ask
- $10.64 / $42.05
- Market Cap
- $7.21 Bil
- Volume/Avg
- 277,658 / 388,042
Key Statistics
- Price/Earnings (Normalized)
- 41.72
- Price/Sales
- 5.97
- Dividend Yield (Trailing)
- 0.23%
- Dividend Yield (Forward)
- 0.26%
- Total Yield
- 0.23%
Company Profile
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 5,635
- Website
- https://www.stevanatogroup.com
Comparables
Valuation
|
Metric
|
STVN
|
PHN
|
AMP
|
|---|---|---|---|
Price/Earnings (Normalized) | 41.72 | 32.41 | 16.12 |
Price/Book Value | 5.61 | 9.17 | 6.44 |
Price/Sales | 5.97 | 4.96 | 3.14 |
Price/Cash Flow | 31.19 | 29.84 | 29.28 |
Price/Earnings
STVN
PHN
AMP
Financial Strength
|
Metric
|
STVN
|
PHN
|
AMP
|
|---|---|---|---|
Quick Ratio | 1.03 | 1.77 | 0.41 |
Current Ratio | 1.50 | 2.12 | 0.48 |
Interest Coverage | 44.75 | 29.60 | 6.90 |
Quick Ratio
STVN
PHN
AMP
Profitability
|
Metric
|
STVN
|
PHN
|
AMP
|
|---|---|---|---|
Return on Assets (Normalized) | 8.40% | 0.01% | 5.00% |
Return on Equity (Normalized) | 14.57% | 0.03% | 16.89% |
Return on Invested Capital (Normalized) | 11.86% | 0.51% | 9.87% |
Return on Assets
STVN
PHN
AMP
Medical Instruments & Supplies Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Tbgqzmdzv | Cfwr | $135.3 Bil | |
BDX
| Becton Dickinson & Co | Nqysxkyp | Svrkjp | $67.8 Bil | |
ALC
| Alcon Inc | Rsndwhp | Tqjxvh | $39.1 Bil | |
RMD
| ResMed Inc | Ncbyjcjyf | Nyspmmf | $31.9 Bil | |
CLPBY
| Coloplast A/S ADR | Vqhblbqtt | Kdvp | $27.8 Bil | |
WST
| West Pharmaceutical Services Inc | Ccyggwydf | Vjwr | $26.7 Bil | |
BAX
| Baxter International Inc | Srzqtrck | Fvmnbh | $18.8 Bil | |
COO
| The Cooper Companies Inc | Jqyvcqrf | Tdcbq | $18.0 Bil | |
HOLX
| Hologic Inc | Ztdvzzpjb | Zpjmkh | $17.9 Bil | |
ATR
| AptarGroup Inc | Ydmbvjgh | Hfbjpdv | $9.7 Bil |